Cynthia Collins

Ms. Collins has more than 40 years of leadership experience in cell and gene therapies and the life sciences. She served as the CEO of Editas Medicine, and was previously the CEO of Human Longevity, Inc.; the CEO/GM of the Cell Therapy and Lab Business of General Electric’s Healthcare Life Sciences; and the CEO of Clarient Diagnostics, Inc. Her prior leadership roles have included President and CEO of GenVec, Inc., a publicly traded vaccine and gene therapy company, and Group Vice President, Cellular Analysis Business of Beckman Coulter. She also served in an earlier role as President and CEO of Sequoia Pharmaceuticals, Inc., a venture funded company developing antiviral drugs for HIV and HCV. Ms. Collins received a B.S. degree in Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business. She is a member of the board of directors at DermTech, Inc., Certara, Biocare Medical, LLC, and Triumvira Immunologics, Inc., and previously served on the boards for the ARM Foundation for Cell and Gene Medicine and the Alliance for Regenerative Medicine.